Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Pyrotinib combined with capecitabine

First Posted Date: 2019-06-28

Last Posted Date: 2022-12-08

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT04001621

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC

Completed

Conditions: Breast Cancer

First Posted Date: 2019-06-28

Last Posted Date: 2024-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 285

Registration Number: NCT04001634

Locations: 🇨🇳
Biyun Wang, MD, Shanghai, Shanghai, China

Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the Bone

Not Applicable

Conditions: Prostate Cancer Metastatic

Interventions: Procedure: Radical prostatectomy plus standard care
Drug: Standard of care for metastatic prostate cancer

First Posted Date: 2019-06-17

Last Posted Date: 2019-06-17

Lead Sponsor: Fudan University

Target Recruit Count: 120

Registration Number: NCT03988686

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC

Phase 2

Completed

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Sintilimab plus Chemotherapy

First Posted Date: 2019-06-13

Last Posted Date: 2024-11-07

Lead Sponsor: Fudan University

Target Recruit Count: 75

Registration Number: NCT03985046

Locations: 🇨🇳
Fudan Universtiy Shanghai Cancer Center, Shanghai, Shanghai, China

Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma

Phase 2

Conditions: Soft Tissue Sarcoma Adult
High Grade Sarcoma

Interventions: Drug: Anlotinib Hydrochloride
Drug: Placebo Oral Tablet

First Posted Date: 2019-05-15

Last Posted Date: 2019-05-15

Lead Sponsor: Fudan University

Target Recruit Count: 88

Registration Number: NCT03951571

Locations: 🇨🇳
Cancer Hospital of Sun Yat-sen, Guangzhou, Guangdong, China
🇨🇳
Yunnan Cancer Hospital, Kunming, Yunnan, China
🇨🇳
The Six People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China

and more 2 locations

Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)

Phase 3

Conditions: Early Breast Cancer

Interventions: Drug: PLD
Drug: CTX
Drug: Docetaxel
Drug: Paclitaxel
Drug: Doxorubicin

First Posted Date: 2019-05-14

Last Posted Date: 2019-05-14

Lead Sponsor: Fudan University

Target Recruit Count: 272

Registration Number: NCT03949634

Locations: 🇨🇳
Fudan University affiliated cancer hospital, Shanghai, China

S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC）

Phase 3

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: S-1 for 9 months
Drug: S-1 for 1 year

First Posted Date: 2019-05-08

Last Posted Date: 2019-05-31

Lead Sponsor: Fudan University

Target Recruit Count: 1006

Registration Number: NCT03941561

Locations: 🇨🇳
Dazhi Xu, Shanghai, China
🇨🇳
First Affiliated Hospital of Wannan Medical College, Wuhu, China
🇨🇳
Anqing Municipal Hospital, Anqing, China

and more 3 locations

Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Phase 2

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Paclitaxel for Injection（Albumin Bound）
Drug: Gemcitabine

First Posted Date: 2019-04-26

Last Posted Date: 2019-04-26

Lead Sponsor: Fudan University

Target Recruit Count: 120

Registration Number: NCT03929094

Locations: 🇨🇳
FUDAN University, Shanghai, Shanghai, China

Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Docetaxel
Drug: Cyclophosphamide

First Posted Date: 2019-04-24

Last Posted Date: 2023-11-14

Lead Sponsor: Fudan University

Target Recruit Count: 2172

Registration Number: NCT03926091

Locations: 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳
The First Bethune Hospital of Jilin University (The First Hospital of Jilin University), Changchun, Jilin, China
🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China

and more 11 locations

Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma

Phase 2

Completed

Conditions: Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma

Interventions: Other: Radiation, Surgery or Radiofrequency ablation
Drug: Systemic therapy

First Posted Date: 2019-04-05

Last Posted Date: 2024-10-23

Lead Sponsor: Fudan University

Target Recruit Count: 104

Registration Number: NCT03904927

Locations: 🇨🇳
Fudan Universtiy Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy